Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|September 29, 2026

The BioPharm Brief: Deals, Data, and a $2 Billion Bet

Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping the biopharmaceutical industry.

Here’s what we have today.

First, Novo Nordisk is adding another oral obesity candidate to its pipeline. The company has licensed global rights outside Greater China to Hengrui Pharma’s HRS-1596, a phase 1-ready GLP-1/GIP dual agonist designed for potentially once-weekly oral dosing. Novo will pay $300 million upfront, with the deal worth up to $2.6 billion in development, regulatory, and commercial milestones, plus royalties. Hengrui has received approval in China to begin phase 1 trials in obesity and type 2 diabetes, although no clinical data have been reported yet.

In Huntington’s disease, uniQure has reported 48-month data for AMT-130. The gene therapy continued to show slowing of disease progression over four years, but the primary endpoint did not reach statistical significance. The company submitted a BLA to FDA earlier this month under the accelerated approval pathway and requested priority review.

And AstraZeneca is putting $2 billion behind Summit Therapeutics and its cancer program. The investment gives AstraZeneca roughly a 12% stake in Summit and comes with a clinical collaboration to test Summit’s PD-1/VEGF bispecific ivonescimab in combination with AstraZeneca ADCs, including the claudin-18.2-targeted sonesitatug vedotin. The companies plan to begin combination trials in gastrointestinal cancers.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit www.BioPharmInternational.com.

Key takeaways

  • Novo is betting on the next wave of oral GLP-1s, licensing a once-weekly candidate from Hengrui in a deal worth up to $2.6 billion.
  • AMT-130 continues to show a signal in Huntington’s disease, but its primary endpoint still missed statistical significance at 48 months.
  • AstraZeneca is putting serious money behind an ADC and bispecific combination strategy, investing $2 billion in Summit and its ivonescimab program.

Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.